Moleculin Biotech
MBRX
21 hedge funds and large institutions have $118K invested in Moleculin Biotech in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 4 closing their positions.
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
5% less funds holding
Funds holding: 22 → 21 (-1)
7.8% less ownership
Funds ownership: 10.56% → 2.76% (-7.8%)
92% less capital invested
Capital invested by funds: $1.44M → $118K (-$1.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$67.6K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$51.4K |
| 3 |
VF
Virtu Financial
New York
|
+$48.6K |
| 4 |
LPL Financial
San Diego,
California
|
+$8.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.56K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.22M |
| 2 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$68.2K |
| 3 |
Barclays
London,
United Kingdom
|
-$335 |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$33 |
MBRX Hedge Fund Activity: Q2 2025 in Review
21 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2025, worth a combined $118K — down 92% from $1.44M a quarter earlier.
Fund positioning in MBRX was balanced in Q2 2025: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 0 trimmed.
The largest buyer was Citigroup, adding an estimated $67.6K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.22M sold.
- 21 institutional investors held Moleculin Biotech (MBRX) as of Q2 2025, down from 22 in Q1 2025.
- Funds reported $118K of Moleculin Biotech stock for Q2 2025, down 92% quarter-over-quarter.
- 4 funds opened new Moleculin Biotech positions in Q2 2025 and 4 closed out, a net change of 0 holders.
- The largest Moleculin Biotech buyer in Q2 2025 was Citigroup, an estimated $67.6K added.
- The largest Moleculin Biotech seller in Q2 2025 was Armistice Capital, an estimated $1.22M sold.
Based on aggregated 13F filings for Q2 2025.